Ameritas Investment Partners Inc. Continues to Hold Position in Cambrex Corporation (CBM)

Ameritas Investment Partners Inc. held its stake in shares of Cambrex Corporation (NYSE:CBM) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,752 shares of the biotechnology company’s stock at the end of the second quarter. Ameritas Investment Partners Inc.’s holdings in Cambrex Corporation were worth $164,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of CBM. Creative Planning boosted its stake in shares of Cambrex Corporation by 162.6% during the 2nd quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 1,093 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Cambrex Corporation by 9.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 150 shares in the last quarter. YorkBridge Wealth Partners LLC lifted its stake in shares of Cambrex Corporation by 5.2% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 97 shares in the last quarter. Riverhead Capital Management LLC lifted its stake in shares of Cambrex Corporation by 90.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,264 shares in the last quarter. Finally, Advisor Group Inc. lifted its stake in shares of Cambrex Corporation by 29.8% during the 2nd quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 615 shares in the last quarter.

In other Cambrex Corporation news, CEO Steven M. Klosk sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $54.96, for a total transaction of $219,840.00. Following the transaction, the chief executive officer now owns 87,328 shares in the company, valued at approximately $4,799,546.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $51.53, for a total transaction of $618,360.00. Following the transaction, the chief executive officer now owns 95,328 shares in the company, valued at approximately $4,912,251.84. The disclosure for this sale can be found here. 2.48% of the stock is currently owned by corporate insiders.

WARNING: This story was published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.com-unik.info/2017/11/04/ameritas-investment-partners-inc-continues-to-hold-position-in-cambrex-corporation-cbm.html.

CBM has been the topic of a number of analyst reports. BidaskClub cut shares of Cambrex Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. ValuEngine downgraded shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, Craig Hallum restated a “buy” rating and issued a $60.00 target price (down from $70.00) on shares of Cambrex Corporation in a report on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Cambrex Corporation presently has a consensus rating of “Hold” and an average target price of $62.33.

Shares of Cambrex Corporation (NYSE:CBM) opened at $44.15 on Friday. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of 14.22, a P/E/G ratio of 0.97 and a beta of 2.26.

Cambrex Corporation Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

What are top analysts saying about Cambrex Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cambrex Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit